Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

612 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Chakravarti A, et al. Among authors: sandler h. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):309-17. doi: 10.1016/j.ijrobp.2004.09.047. Int J Radiat Oncol Biol Phys. 2005. PMID: 15890569
Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.
Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Thames H, et al. Among authors: sandler h. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):929-43. doi: 10.1016/s0360-3016(03)00631-x. Int J Radiat Oncol Biol Phys. 2003. PMID: 14575823
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Kupelian P, et al. Among authors: sandler h. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9. doi: 10.1016/j.ijrobp.2004.05.018. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667961
Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D. Kupelian P, et al. Among authors: sandler h. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. doi: 10.1016/j.ijrobp.2005.03.029. Epub 2005 May 31. Int J Radiat Oncol Biol Phys. 2005. PMID: 15925452
Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.
Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H. Feigenberg SJ, et al. Among authors: sandler h. Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):956-64. doi: 10.1016/j.ijrobp.2004.12.061. Int J Radiat Oncol Biol Phys. 2005. PMID: 15989995 Clinical Trial.
A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019.
Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H. Lee WR, et al. Among authors: sandler h. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):804-9. doi: 10.1016/j.ijrobp.2005.09.002. Epub 2005 Nov 14. Int J Radiat Oncol Biol Phys. 2006. PMID: 16289906 Clinical Trial.
612 results